| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/RHEUMATOLOGY/41.6.658 |
| P698 | PubMed publication ID | 12048292 |
| P50 | author | Henk J Blom | Q39861503 |
| P2093 | author name string | van de Putte LB | |
| Thomas CM | |||
| Boers GH | |||
| Haagsma CJ | |||
| Laan RF | |||
| van Ede AE | |||
| De Boo TM | |||
| P2860 | cites work | Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity | Q41757845 |
| Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity | Q43483478 | ||
| Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study | Q43683228 | ||
| A toxicity index for comparison of side effects among different drugs | Q45009872 | ||
| Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? | Q51589418 | ||
| Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study | Q51607054 | ||
| Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. | Q51618666 | ||
| A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease | Q57268055 | ||
| A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase | Q24324172 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score | Q33563148 | ||
| Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients | Q33578306 | ||
| Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence | Q33727775 | ||
| Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease | Q34049313 | ||
| Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati | Q34662758 | ||
| Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis | Q35548424 | ||
| The cellular pharmacology of methotrexate | Q38154647 | ||
| Methotrexate use in rheumatoid arthritis | Q40878401 | ||
| The mechanism of action of methotrexate | Q41635846 | ||
| P433 | issue | 6 | |
| P921 | main subject | folic acid | Q127060 |
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 658-665 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis | |
| P478 | volume | 41 |
| Q46885439 | 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis |
| Q44421209 | Anemia, serum vitamin B12, and folic acid in patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus |
| Q43578147 | Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study |
| Q89891732 | Association of Serum Folate Levels With Cardiovascular Mortality Among Adults With Rheumatoid Arthritis |
| Q88801159 | Association of hyperhomocysteinemia with genetic variants in key enzymes of homocysteine metabolism and methotrexate toxicity in rheumatoid arthritis patients |
| Q44621683 | Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate |
| Q35553376 | Atherosclerotic cardiovascular disease in rheumatoid arthritis |
| Q46255850 | Bone marrow and adipose mesenchymal stem cells attenuate cardiac fibrosis induced by methotrexate in rats |
| Q38568465 | Cardiovascular comorbidity in rheumatic diseases |
| Q38813397 | Cardiovascular risk in patients with rheumatoid arthritis |
| Q41934162 | Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients |
| Q90135380 | Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia |
| Q31006990 | Diet and psoriasis: experimental data and clinical evidence |
| Q35605663 | Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study |
| Q33633643 | Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors |
| Q37267458 | Effects of Methotrexate in a Rabbit Model of In-Stent Neoatherosclerosis: An Optical Coherence Tomography Study. |
| Q36028335 | Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria |
| Q48307126 | Folate deficiency in north Indian children undergoing maintenance chemotherapy for acute lymphoblastic leukemia-Implications and outcome. |
| Q37369929 | Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. |
| Q35794642 | Homocysteine and lipid profile in children with Juvenile Idiopathic Arthritis. |
| Q34163760 | Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency |
| Q37866668 | Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center |
| Q64890940 | Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. |
| Q35636960 | Methotrexate modulates the kinetics of adenosine in humans in vivo |
| Q35553306 | Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene |
| Q54372512 | Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q36417062 | Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of literature |
| Q35911142 | Pharmacogenetics of methotrexate |
| Q88790397 | Pharmacogenomics in the treatment of rheumatoid arthritis: clinical implication and perspective |
| Q35049306 | Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases |
| Q46090014 | Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis. |
| Q90599771 | Possible Modulation of Vascular Function Measures in Rheumatoid Arthritis by Homocysteine |
| Q53502883 | Prevention of stroke in rheumatoid arthritis. |
| Q36677248 | Recommendations for the use of methotrexate in juvenile idiopathic arthritis |
| Q46555806 | Reducing toxicity of methotrexate with folic acid |
| Q37140079 | Rheumatoid arthritis and cardiovascular disease |
| Q36040885 | Rheumatoid disease and the heart: from epidemiology to echocardiography |
| Q89000380 | Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury |
| Q38098061 | The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA. |
| Q46830299 | The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. |
| Q37640953 | The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review |
| Q61454160 | The effects of conventional drugs in the treatment of rheumatoid arthritis on the serum lipids |
| Q33547329 | The role of endothelial function and its assessment in rheumatoid arthritis. |
| Q36027291 | Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients. |
| Q36577503 | Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis |
| Q36758644 | Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine |
| Q99631226 | Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy |
| Q33564092 | Venous thrombosis and prothrombotic factors in inflammatory bowel disease |
| Q84396532 | When should we use parenteral methotrexate? |
Search more.